Name

Nova Laboratories

Legal name

Nova Laboratories Ltd

Website

https://novalabs.co.uk

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Sterile Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF), Release Testing & Batch Certification (QC) (HLAGADAC), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)

Keywords

• Sterile pharmaceutical manufacturing
• Aseptic contract manufacturing
• Specials medicines compounding
• Drug stabilisation technologies
• Specialty pharmaceutical products

Headquarters

HQ city

Wigston

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

1. Contract Manufacturing Services: Provides contract sterile manufacturing, fill/finish, and 'Specials' manufacturing services to pharmaceutical, biopharmaceutical, and medical device companies. Includes 'turnkey' solutions with in-house analytical and microbiological testing, clinical trial labelling and packaging, and QP release.
2. Nova Licensed Products: Develops, manufactures, and distributes Nova-branded medicines for niche and rare diseases with Marketing Authorisations in UK, EU, USA and ROW. Includes liquid versions of existing medicines for precision dosing and paediatrics.
3. 'Specials' Medicines: Formulates, compounds, and packages bespoke 'Specials' medicines tailored to patients with clinically complex medical conditions. Supplies to NHS, healthcare providers, and veterinary sector.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels1 record

Core offering

Nova Laboratories is a pharmaceutical manufacturer providing contract sterile manufacturing services (aseptic fill/finish, spray drying, clinical trial manufacturing) to pharmaceutical, biopharmaceutical and medical device companies, alongside its own Nova-branded licensed medicines for niche and rare diseases and bespoke 'Specials' compounding for individual patient needs. Its proprietary HydRIS® and VitRIS® platforms stabilise temperature-sensitive APIs, supported by in-house QC testing, microbiological services, clinical trial labelling/packaging and QP release.

Product overview

Nova Laboratories is a diversified pharmaceutical manufacturing company offering four interconnected service/product areas: Nova Licensed Products (proprietary branded medicines for niche and rare diseases), Sterile Manufacturing (contract aseptic manufacturing including fill/finish and spray drying), 'Specials' Manufacturing (bespoke medicines for individual patient needs), and Stabilisation Technologies (HydRIS® and VitRIS® platforms for temperature-sensitive products). The company operates as both a contract manufacturer and a product developer, with capabilities spanning from early-phase clinical trials through to commercial-scale production.

Differentiator

Problem solved

Functional benefit

Products and services

• Nova Licensed Products Nova-branded medicines for the treatment of niche and rare diseases, including liquid versions of existing medicines for precision dosing and paediatrics, with Marketing Authorisations in the UK, EU, USA and ROW. Targeted at healthcare providers, community pharmacies, and patients with rare diseases.
• Sterile Manufacturing (Contract Aseptic Manufacturing Services) Contract aseptic manufacturing services for pharmaceutical, biopharmaceutical and medical device companies, covering routine fill/finish from small hand-filled batches to semi-automated batches of up to 10,000 vials, spray drying, and processing of complex products including small molecules, peptides, proteins, antibodies, live biologicals, and gene therapies. Includes 'turnkey' solutions with in-house analytical and microbiological testing, clinical trial labelling and packaging, and QP release.
• 'Specials' Manufacturing Bespoke 'Specials' medicines formulated, compounded, and packaged to the needs of patients with clinically complex medical conditions. Includes solutions, suspensions, mixtures, creams, ointments, lotions, capsules, suppositories, enemas, nasal drops, cytotoxic products, and controlled drugs. Supplied to NHS hospitals, healthcare providers, the veterinary sector, and via Nova Laboratories Ireland for EU customers.
• HydRIS® Stabilisation Platform Proprietary Hypodermic Rehydration Injection System that dries a formulated solution or suspension of an unstable API around filaments of a small section of filter membrane to create ultra-thin sheaths and webs of dried, stabilised product, enabling dramatic increase in thermal stability with single-action reconstitution and injection. Used for low volume injectables including vaccines, live viral and bacterial products.
• VitRIS® Stabilisation Platform Proprietary Vitrified Readily Injectable Suspension platform using aseptic spray drying to produce thermo-stable spherical particles of a formulated solution or suspension of an unstable API. Particles can be engineered to match the density of a non-aqueous injectable vehicle for stable suspension, addressing thermal instability and storage challenges for temperature-sensitive medicines.

Quantifiable outcome

• Routine liquid fill/finish from small hand-filled batches to semi-automated batches of up to 10,000 vials
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Nova Laboratories IrelandcoreStrategic or Co-development Partner · 1 January 2021Sister company established to continue supply of products to the EU following Brexit. Handles EU import testing and QP release before distribution within the EU community. Became operational in 2021.

Scale indicators6 records

Recent moves12 records

Expansion highlights5 records

Direct peers

• Symbiosis Pharmaceutical Services: UK-based CDMO specializing in sterile injectable fill-finish for clinical trials and small-batch commercial supply. Directly comparable as a UK-headquartered specialist in aseptic manufacturing and clinical trial material production.
• Vetter Pharma: German-headquartered specialist CDMO focused on aseptic fill-finish of complex injectable biologics. Comparable in its deep specialization in sterile aseptic processing, complex formulation challenges, and regulatory-grade quality systems serving biopharma clients.
• Upperton Pharma Solutions: UK-based specialist CDMO focused on formulation development and clinical trial manufacturing, including sterile and aseptic processing. Comparable as a UK-headquartered emerging CDMO serving similar early-phase and niche commercial pharmaceutical clients.
• Sterling Pharma Solutions: UK-based CDMO providing API development, manufacturing, and contract services across small molecules and increasingly complex modalities. Comparable as a UK-headquartered mid-sized contract manufacturer serving pharmaceutical and biopharmaceutical clients.
• Corden Pharma: European CDMO with strong capabilities in complex injectables, peptides, and sterile manufacturing. Comparable in its specialization in complex aseptic formulations and contract manufacturing for pharmaceutical clients.

Broad incumbents

• Almac Group: Northern Ireland-headquartered global CDMO offering sterile manufacturing, clinical trial supply, and analytical services. Overlaps with Nova's contract manufacturing, clinical trial material, and analytical testing capabilities, but at significantly larger scale and broader geographic reach.
• PCI Pharma Services: Global CDMO offering sterile fill-finish, clinical trial services, and specialty manufacturing. Comparable in sterile injectable manufacturing and clinical trial material supply, but operates at substantially larger scale and geographic breadth.
• Catalent: Global CDMO with extensive sterile injectable fill-finish and biopharma capabilities, including gene therapy and cell therapy manufacturing. Comparable across Nova's aseptic manufacturing and novel modality offerings, but at a vastly larger global scale.
• Recipharm: European-headquartered CDMO offering sterile fill-finish, biologics, and contract manufacturing services. Comparable as a contract manufacturing peer in sterile injectable production, though at significantly larger scale and broader service portfolio.
• Siegfried Holding: Swiss-headquartered CDMO offering API and finished dose manufacturing including sterile injectable capabilities. Comparable as a European contract manufacturer with sterile production capabilities serving pharmaceutical clients.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/nova-laboratories-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nova Laboratories